Semax vs Selank — Russian Nootropic Heptapeptide Comparison

Semax and Selank are the two most studied Russian nootropic heptapeptides. Both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences within the same research programme, share the same seven-residue length, the same primary delivery route, and the same general class designation. Yet their mechanisms and research indications point in opposite directions: Semax drives cognitive activation and neurotrophic factor expression, while Selank attenuates anxiety through GABAergic modulation without the receptor downregulation associated with classical anxiolytics. Understanding where the two compounds diverge — and where they converge — is the core question that determines which is appropriate for a given research context.

Shared origin, different targets

Both peptides were engineered using the same structural logic. A biologically active peptide fragment of known endogenous origin was identified, then extended at the C-terminus with a Pro-Gly-Pro motif to slow enzymatic degradation and extend effective half-life without altering the pharmacological character of the parent sequence. For Semax the parent was ACTH(four to ten), a fragment of adrenocorticotropic hormone that produces cognitive effects in rodent models independently of corticotropic adrenal signalling [PMID:1805857]. For Selank the parent was tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide cleaved from the Fc region of IgG immunoglobulin, which showed modest anxiolytic properties in early animal studies but was too short-lived in plasma to be pharmacologically exploitable [PMID:22662104].

The result of this parallel design process was two heptapeptides that are structurally analogous in form but mechanistically distinct in target. Semax (Met-Glu-His-Phe-Pro-Gly-Pro, molecular weight 813.9 Da) operates primarily through neurotrophic and monoaminergic pathways. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, molecular weight 751.9 Da) operates primarily through GABAergic and enkephalinergic pathways. This mechanistic non-overlap is what makes the two compounds rationally combinable in protocols targeting both cognitive performance and anxiety simultaneously.

Mechanism of action — Semax

Semax engages the central nervous system through three documented primary mechanisms.

BDNF and NGF upregulation is the most extensively characterised effect. Levitskaya and colleagues demonstrated that Semax reliably increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in hippocampal CA1-CA3 regions and prefrontal cortex following both intranasal and intraperitoneal administration in rodent ischaemic models [PMID:25323565]. BDNF is a master regulator of synaptic plasticity, long-term potentiation, and neuronal survival; its upregulation underpins the improved spatial memory, working-memory consolidation, and resistance to excitotoxic injury that characterise Semax's cognitive profile across species.

Monoaminergic activation is the second core mechanism. Eremin and colleagues showed that Semax selectively increases dopaminergic signalling in the striatum and serotonergic tone in hippocampal and frontal regions at doses achievable by intranasal delivery [PMID:16362768]. This dual monoamine engagement produces the alerting, attentional, and motivational profile associated with Semax and distinguishes it pharmacologically from pure neurotrophic agents — it is both acutely activating and durably neurotrophic.

Melanocortin pathway modulation is a secondary mechanism arising from Semax's ACTH lineage. Because the heptapeptide retains partial affinity for melanocortin receptors expressed in the CNS (particularly MC-four and MC-five subtypes), it participates in anti-inflammatory and neuroprotective signalling without engaging the adrenal MC-two receptor responsible for cortisol release. This explains why Semax is not a steroidogenic compound despite sharing sequence homology with ACTH, and why it was found to be neuroprotective in stroke models even when administered after the ischaemic event [PMID:10774073].

Mechanism of action — Selank

Selank's pharmacology is equally multi-mechanism but oriented toward inhibitory rather than activating neurotransmission.

GABAergic potentiation is Selank's primary action. It enhances GABA-A receptor function through a mechanism that does not involve direct binding to the benzodiazepine allosteric site [PMID:22662104]. This distinction is clinically significant: benzodiazepine-site ligands produce receptor downregulation, tolerance, and physical dependence with sustained use; Selank's GABAergic modulation proceeds by a different route and has not been associated with tolerance or withdrawal phenomena in any published animal-model or human clinical series extending up to three to four weeks.

Enkephalin stabilisation provides a second anxiolytic and mood-stabilising mechanism. Semenova and colleagues demonstrated that Selank inhibits enkephalin-degrading enzymes — primarily dipeptidyl peptidase IV — elevating endogenous met-enkephalin and leu-enkephalin in limbic tissue [PMID:11830764]. Elevated central enkephalin tone contributes to anxiolysis and emotional stabilisation through mu and delta opioid receptor activation without the respiratory depression or addiction liability associated with exogenous opioids; Selank does not bind opioid receptors directly.

Serotonergic enhancement and BDNF upregulation round out Selank's mechanistic profile. Semenova's work documented increased serotonin turnover in the amygdala and hippocampus [PMID:11830764], and Kolomin and colleagues identified BDNF upregulation at the transcriptional level in cortical and hippocampal tissue following repeated Selank administration [PMID:24349829]. This BDNF-upregulating activity means Selank is not purely anxiolytic — it shares a neurotrophic axis with Semax, though the amplitude of Selank's BDNF effect in preclinical literature appears smaller than Semax's. The serotonergic component provides a theoretical basis for mood-stabilising and antidepressant-adjacent effects that extend beyond acute anxiolysis.

Evidence base

Semax has the stronger translational evidence base of the two compounds. The Skvortsova Phase II randomised controlled trial [PMID:10774073] administered intranasal Semax to patients with acute ischaemic stroke and documented statistically significant improvements in National Institutes of Health Stroke Scale scores at thirty and ninety days compared to standard care. This Phase II human trial is the most methodologically rigorous piece of evidence in the nootropic-peptide literature originating from Russia, and it secured Semax's position on the Russian Federation essential medicines list for post-stroke rehabilitation. Earlier preclinical work by Eremin et al. [PMID:16362768] confirmed monoaminergic activation at intranasal doses, and Levitskaya's BDNF data [PMID:25323565] provided the mechanistic explanation for the clinical neuroprotective observations. Potaman and colleagues established intranasal pharmacokinetics, demonstrating that nasal mucosal delivery achieves detectable central concentrations without systemic hormonal exposure [PMID:1805857].

Selank has a robust preclinical literature and a smaller but meaningful human evidence base. The primary clinical dataset comes from Russian Phase II and Phase III trials conducted at the Serbsky National Medical Research Centre for Psychiatry comparing Selank against the benzodiazepine fenazepam in generalised anxiety disorder. These trials documented equivalent anxiolytic efficacy on the Hamilton Anxiety Rating Scale with substantially less sedation and no measurable physiological dependence at end-of-protocol — the defining finding that distinguishes Selank from its comparator. Kozlovskaya and colleagues [PMID:14968163] characterised Selank's anxiolytic and antidepressant-like profile in rodent behavioural pharmacology paradigms, and Sudakov's learned-helplessness post-traumatic stress model data [PMID:15378174] extended the preclinical characterisation to chronic-stress contexts. Full Phase III datasets have not been published in peer-reviewed English-language journals, which limits independent evaluation.

Neither compound has been evaluated in any randomised controlled trial outside the Russian Federation. Both are unapproved research compounds in the United Kingdom, the United States, and the European Union.

Dosing — research protocols

Semax research dosing in the Russian clinical literature centres on 300–600 µg/day administered intranasally across two sessions. A standard protocol divides the daily dose across morning (150–300 µg) and midday (150–300 µg) administrations. Cycle length in validated Russian protocols is two to four weeks, with equivalent rest periods between cycles. The rationale for twice-daily dosing is the short plasma half-life of the peptide — single daily loading produces a truncated effect window. Semax is commercially available as a 0.1% intranasal solution (one milligram per millilitre), with each standard spray delivering approximately 100 µg per actuation; researchers working with lyophilised powder reconstitute to the same concentration in sterile saline.

Selank research dosing centres on 400–800 µg/day administered intranasally, similarly divided across two sessions. The standard Russian formulation is a 0.15% intranasal solution (one and a half milligrams per millilitre), where each drop from a standard dropper delivers approximately 75 µg per nostril. The lower end of the range is typically sufficient for anxiolytic effect; the upper end is used when immunomodulatory or nootropic properties are the primary research interest. Cycle length mirrors Semax: two to four weeks, cycling off for an equivalent interval.

When the two compounds are researched together — as in the complementary half-day stack protocol — they are administered simultaneously via separate nasal atomisers, as no pharmacokinetic interaction between the two heptapeptides has been identified.

Safety profile

Both compounds have unusually clean safety records by the standards of nootropic research peptides, attributable in part to three decades of regulated human clinical use in Russia.

The most commonly reported adverse effect for both is mild transient nasal mucosal irritation — rhinorrhoea, brief burning sensation, or mild congestion — that typically diminishes within minutes of administration and decreases further with repeated use as the mucosa adapts. Neither compound has been associated with dependence, withdrawal phenomena, addiction-related behaviour, or organ toxicity in any published series.

The key safety distinction between the two lies in their interaction with monoaminergic versus inhibitory tone. Semax produces a mild activating signal through dopaminergic and noradrenergic pathways; researchers with pre-existing anxiety, cardiovascular reactivity, or sensitivity to stimulating compounds may find the activating signal subjectively prominent at the higher end of the dosing range. Selank, by contrast, produces a calming GABAergic signal, which in combination with other CNS depressants (including benzodiazepines) could theoretically produce additive sedation. Neither compound should be combined with monoamine oxidase inhibitors given the theoretical risk of monoaminergic excess from Semax's dopaminergic and serotonergic activity.

Neither Semax nor Selank is approved by the UK Medicines and Healthcare products Regulatory Agency for human medicinal use. Both are available in the United Kingdom for in vitro laboratory research only.

When to choose Semax vs Selank

Research context determines which compound is the more appropriate subject of study.

Semax is the more appropriate choice when the primary research question involves cognitive enhancement — specifically working-memory consolidation, sustained attention, or processing speed — or when the question is neuroprotective: post-ischaemic recovery, BDNF-dependent neuroplasticity, or monoaminergic deficit models. Its Phase II human stroke RCT data makes it the more clinically translatable of the two compounds and the one more likely to produce measurable cognitive effects in healthy-subject cognitive paradigms.

Selank is the more appropriate choice when the primary research question is anxiolytic — attenuating conditioned fear, reducing stress-reactivity, or examining GABA-A modulation without receptor downregulation. It is specifically indicated where a benzodiazepine-free anxiolytic mechanism is the experimental requirement, or where the combination of anxiolysis and preserved cognitive performance (absent the impairment produced by classical benzodiazepines) is the research endpoint.

Both together is the most commonly reported research configuration in the Russian nootropic literature precisely because cognitive performance and anxiety are not independent variables. When cognitive tasks are performed under conditions of anticipatory stress or social evaluation threat, Semax's activating signal and Selank's anxiolytic counterweight interact to produce a combined profile that neither delivers alone.

Sourcing

Both Semax and Selank are available as research compounds from specialist peptide suppliers. Semax is most commonly supplied as a pre-dissolved 0.1% intranasal spray; Selank as a pre-dissolved 0.15% intranasal solution. Researchers should verify peptide purity via third-party high-performance liquid chromatography and mass spectrometry certificates of analysis before use. Cold-chain delivery (refrigerated shipping) is appropriate for solution preparations; lyophilised powder is stable at ambient temperature during transit but should be refrigerated once reconstituted. Storage at two to eight degrees Celsius with protection from light is standard for both compounds; reconstituted solutions should be used within thirty days.

---

For the combined three-peptide cognitive and anxiolytic protocol pairing Semax and Selank with the pineal neuroprotective tripeptide Pinealon, see the Semax + Selank + Pinealon Nootropic Stack. For the sleep-and-anxiety protocol pairing Selank with delta sleep-inducing peptide, see the DSIP + Selank Sleep Stack.

Verdict — research-question matching

Semax and Selank are complementary rather than competing research choices. Choose Semax when the primary research question centres on cognitive enhancement, BDNF upregulation, working-memory consolidation, or neuroprotection following ischaemic insult — the compound's documented clinical use in post-stroke rehabilitation gives it the stronger translational evidence base. Choose Selank when the primary question is anxiolysis, stress-reactivity attenuation, or the reduction of performance-degrading anticipatory anxiety without benzodiazepine-type dependence risk. When both questions apply simultaneously — cognitive performance under anxiogenic conditions — the two peptides are most usefully studied together, because their mechanisms (BDNF/monoaminergic vs GABAergic/enkephalinergic) are non-overlapping and the combination is the basis of the complementary half-day protocol described in the Semax + Selank + Pinealon nootropic stack.